EUCTR2014-002124-27-DKActive, not recruitingPhase 1
GLP-1 Agonist and Bone: Effects of Exenatide on Bone Metabolism - GAB-E
Endocrine Research Unit, Odense University Hospital0 sitesStarted: October 1, 2014Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional clinical trial of medicinal product
Eligibility Criteria
- Sex
- Female
Inclusion Criteria
- •healthy postmenopausal women
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range 66
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 66
Exclusion Criteria
- •-primary hyperparathyroidism
- •- treatment with metformin or any other drug used for the treatment of type 2 diabetes, antiresorptive drugs, glucocorticoids, aromatase inhibitors, HRT, anti-epileptic drugs
- •- diseases associated with osteoporosis including RA, renal insufficiency, thyreotoxicosis, type 1 diabetes, severe COPD
- •- pancreatitis
- •- fractures < 6 months
- •- allergy towards exenatide
- •- excessive intake of alcohol
Investigators
Similar Trials
Active, not recruiting
Phase 1
To investigate whether treatment with the GLP-1 receptor agonist exenatide improves the perception of hypoglycaemia in people with type 1 diabetes with impaired awareness of hypoglycaemiaType 1 diabetesEUCTR2016-000790-21-NLRadboudumc15
Completed
Phase 2
Effect of the GLP-1 receptor agonist exenatide on impaired awareness of hypoglycemia in type 1 diabetesDiabetesNL-OMON45806Radboud Universitair Medisch Centrum13
Active, not recruiting
Phase 1
Effet d’un agoniste du récepteur au GLP1 (Exenatide) sur le contenu en triglycérides intramyocardique chez le patient obèse diabétique.patient obèse diabétiqueEUCTR2010-022792-57-FRASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE40
Recruiting
Not Applicable
Clinical study of GLP-1 receptor agonist (Exenatide) for type 2 diabetes patients with diabetic nephropathyJPRN-UMIN000037106Kagawa University30
Completed
Not Applicable
The Effect of GLP-1 Receptor Activation on Central Reward and Satiety in Obesity and DiabetesDiabetes MellitusObesityDiabetes Mellitus, Type 2NCT01281228Amsterdam UMC, location VUmc48